Led by Ludwig Lausanne investigator Alexandre Harari and George Coukos, director of the Ludwig Institute for Cancer Research, Lausanne, the study shows that
ovarian tumors harbor highly reactive killer T cells — which kill infected and cancerous cells — and demonstrates how they can be identified and selectively grown for use in personalized, cell - based immunotherapies.